PharmaJet®, a World Leader in Needle-free Injection Systems, is Initiating the Development of Needle-free Self-Injection Pens for Home Use
- Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use.
- PharmaJet injector pens are intended for needle-free subcutaneous delivery of a wide range of pharmaceuticals, which could include metabolic peptides, hormones, small molecules, and antibodies.
GOLDEN, Colorado — October 7, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. Prototypes of the subcutaneous (SC) injectors, aimed at the chronic disease and metabolic peptide self-injection markets, are currently in early testing.
Self-injectable drug delivery provides important benefits to patients, caregivers, and health systems. However, needle-aversion and injection site pain are significant barriers that impact compliance. PharmaJet’s needle-free injector pens aim to improve the user experience, reduce administration anxiety and discomfort, and simplify the injection procedure, especially for patients with mobility challenges. Importantly, the reusable PharmaJet injector pens may offer significant advantages over current disposable technologies that generate enormous waste.
